Calculation
Net profit margin | = | 100 | × | Net income attributable to Pfizer Inc.1 | ÷ | Revenues1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2023 | 3.62% | = | 100 | × | 2,119) | ÷ | 58,496) |
Dec 31, 2022 | 31.27% | = | 100 | × | 31,372) | ÷ | 100,330) |
Dec 31, 2021 | 27.04% | = | 100 | × | 21,979) | ÷ | 81,288) |
Dec 31, 2020 | 22.95% | = | 100 | × | 9,616) | ÷ | 41,908) |
Dec 31, 2019 | 31.45% | = | 100 | × | 16,273) | ÷ | 51,750) |
Dec 31, 2018 | 20.79% | = | 100 | × | 11,153) | ÷ | 53,647) |
Dec 31, 2017 | 40.55% | = | 100 | × | 21,308) | ÷ | 52,546) |
Dec 31, 2016 | 13.66% | = | 100 | × | 7,215) | ÷ | 52,824) |
Dec 31, 2015 | 14.25% | = | 100 | × | 6,960) | ÷ | 48,851) |
Dec 31, 2014 | 18.42% | = | 100 | × | 9,135) | ÷ | 49,605) |
Dec 31, 2013 | 42.65% | = | 100 | × | 22,003) | ÷ | 51,584) |
Dec 31, 2012 | 24.70% | = | 100 | × | 14,570) | ÷ | 58,986) |
Dec 31, 2011 | 14.84% | = | 100 | × | 10,009) | ÷ | 67,425) |
Dec 31, 2010 | 12.18% | = | 100 | × | 8,257) | ÷ | 67,809) |
Dec 31, 2009 | 17.27% | = | 100 | × | 8,635) | ÷ | 50,009) |
Dec 31, 2008 | 16.78% | = | 100 | × | 8,104) | ÷ | 48,296) |
Dec 31, 2007 | 16.82% | = | 100 | × | 8,144) | ÷ | 48,418) |
Dec 31, 2006 | 39.98% | = | 100 | × | 19,337) | ÷ | 48,371) |
Dec 31, 2005 | 15.76% | = | 100 | × | 8,085) | ÷ | 51,298) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
Comparison to Competitors
Pfizer Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2023 | 3.62% | 8.95% | 24.96% | 17.83% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | 30.14% | 13.99% |
Dec 31, 2022 | 31.27% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 35.64% | 15.47% |
Dec 31, 2021 | 27.04% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 50.25% | 19.70% |
Dec 31, 2020 | 22.95% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 41.35% | 19.79% |
Dec 31, 2019 | 31.45% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 26.91% | 14.47% |
Dec 31, 2018 | 20.79% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 36.42% | 12.06% |
Dec 31, 2017 | 40.55% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 20.41% | 10.64% |
Dec 31, 2016 | 13.66% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 18.42% | 11.06% |
Dec 31, 2015 | 14.25% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 15.50% | 11.64% |
Dec 31, 2014 | 18.42% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 12.34% | 11.22% |
Dec 31, 2013 | 42.65% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 20.16% | 9.73% |
Dec 31, 2012 | 24.70% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 54.43% | 9.42% |
Dec 31, 2011 | 14.84% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | -49.74% | 11.34% |
Dec 31, 2010 | 12.18% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | -22.76% | 9.60% |
Dec 31, 2009 | 17.27% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | -17.88% | 8.41% |
Dec 31, 2008 | 16.78% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | -34.69% | 9.47% |
Dec 31, 2007 | 16.82% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | -84.46% | 7.81% |
Dec 31, 2006 | 39.98% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | -161.30% | 4.46% |
Dec 31, 2005 | 15.76% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | -144.19% | 8.48% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Pfizer Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Pfizer Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2023 | 3.62% | 17.60% |
Dec 31, 2022 | 31.27% | 22.34% |
Dec 31, 2021 | 27.04% | 23.31% |
Dec 31, 2020 | 22.95% | 13.63% |
Dec 31, 2019 | 31.45% | 23.16% |
Dec 31, 2018 | 20.79% | 19.40% |
Dec 31, 2017 | 40.55% | 13.08% |
Dec 31, 2016 | 13.66% | 20.92% |
Dec 31, 2015 | 14.25% | 21.42% |
Dec 31, 2014 | 18.42% | 21.52% |
Dec 31, 2013 | 42.65% | 22.24% |
Dec 31, 2012 | 24.70% | 18.66% |
Dec 31, 2011 | 14.84% | 15.76% |
Dec 31, 2010 | 12.18% | 15.46% |
Dec 31, 2009 | 17.27% | 26.03% |
Dec 31, 2008 | 16.78% | 18.39% |
Dec 31, 2007 | 16.82% | 16.10% |
Dec 31, 2006 | 39.98% | 22.37% |
Dec 31, 2005 | 15.76% | 18.45% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Pfizer Inc. | Health Care | |
---|---|---|
Dec 31, 2023 | 3.62% | 7.95% |
Dec 31, 2022 | 31.27% | 10.17% |
Dec 31, 2021 | 27.04% | 10.82% |
Dec 31, 2020 | 22.95% | 7.69% |
Dec 31, 2019 | 31.45% | 10.13% |
Dec 31, 2018 | 20.79% | 9.17% |
Dec 31, 2017 | 40.55% | 7.75% |
Dec 31, 2016 | 13.66% | 9.91% |
Dec 31, 2015 | 14.25% | 10.98% |
Dec 31, 2014 | 18.42% | 11.39% |
Dec 31, 2013 | 42.65% | 11.99% |
Dec 31, 2012 | 24.70% | 11.19% |
Dec 31, 2011 | 14.84% | 10.02% |
Dec 31, 2010 | 12.18% | 10.09% |
Dec 31, 2009 | 17.27% | 14.33% |
Dec 31, 2008 | 16.78% | 10.62% |
Dec 31, 2007 | 16.82% | 10.58% |
Dec 31, 2006 | 39.98% | 13.20% |
Dec 31, 2005 | 15.76% | 12.89% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).